Validation of the MOG-AR Score: A Retrospective Multicenter Study

Area of Science:

• Neurology
• Immunology
• Clinical Research

Background:

• Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an autoimmune condition.
• Identifying patients at high risk of relapse is crucial for timely intervention.
• The MOG-AR score was developed to predict relapse risk in MOGAD.

Purpose of the Study:

• To validate the MOG-AR score in a multicenter cohort of MOGAD patients.
• To identify other factors associated with relapse risk in MOGAD.

Main Methods:

• Retrospective enrollment of 190 MOGAD patients from 24 centers.
• Application of the MOG-AR score to categorize patients into 4 risk levels.
• Statistical analysis to explore the association of MOG-AR score and other variables with relapse.

Main Results:

• The MOG-AR score showed limited accuracy in predicting relapses (AUC=0.64).
• 41% of patients experienced at least one relapse during follow-up.
• Immunosuppressive treatment post-initial MOGAD attack was associated with a lower relapse risk.

Conclusions:

• The MOG-AR score is not a reliable predictor of disease course in MOGAD.
• Early immunosuppressive treatment may reduce relapse rates in MOGAD patients.